2016
Enzymatics Inc. (2013 - 2015)
Beverly, MA | CEO
Stemgent Inc. (2008 - 2013)
Cambridge, MA | Founder, CEO
Upstate Inc. (2002 - 2004)
Charlottesville, VA | President
University of Virginia
MBA | Darden School
University of Surrey
Chemical Engineering
Ian is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture and private equity investor. Ian has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately-held Life Science product and service businesses. He has focused on the cell signaling, drug screening, genomics and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sell. Prior to joining Sands Capital, Ian was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tool, and President of Upstate Inc., a leading provider of cell signaling research products and services. Ian was also a founding investor in Firefly Bioworks and Genometry, both SCV investments. Ian has a degree in Chemical Engineering from University of Surrey and has a MBA from the Darden School at the University of Virginia.
Sands Capital consists of the combination of Sands Capital Management, LLC and Sands Capital Ventures, LLC. Sands Capital operates as a distinct business organization, retains discretion over the assets between the two registered investment advisers, and has autonomy over the total investment decision making process. The private markets investment strategies discussed herein are executed by Sands Capital Ventures with certain resources, including staff, provided by Sands Capital Management.
*AUM includes the discretionary and non-discretionary assets of Sands Capital Management, LLC as of December 31, 2022, and the gross assets of all funds (not including uncalled capital) for Sands Capital Ventures, LLC. Figures for Sands Capital Ventures LLC are updated 45-60 days after quarter-end.
The information presented on this website is informational only and is not to be construed, by any means, to be an offering, solicitation, advertisement or marketing material to purchase securities or interests in any investment vehicle advised by Sands Capital. Such an offer will only be made by means of a Confidential Private Offering Memorandum, which will be available solely on request, on an exclusively private basis and only to qualified financially sophisticated investors, which contains important information (including investment objectives, policies, risk factors, fees, tax implications and relevant qualifications), and only in those jurisdictions where permitted by law.
Sands Capital
1000 Wilson Boulevard, Suite 3000
Arlington, Virginia 22209 USA
1.703.562.4000
Sands Capital is an active, long-term investor in leading innovative businesses globally. Our approach combines analytical rigor and creative thinking to identify high-quality growth businesses that are creating the future. Through an integrated investment platform spanning venture capital, growth equity, and public equity, we provide growth capital solutions to institutions and fund sponsors in more than 40 countries.
An independent, staff-owned firm founded in 1992 and headquartered in the Washington, D.C. area with offices in London and Singapore, Sands Capital managed more than $43.8 billion* in client assets as of December 31, 2022.
© 2022 Sands Capital. All Rights Reserved.
